CELF6 as an Oncogene in Colorectal Cancer: Targeting Stem-Cell-Like Properties Through Modulation of HOXA5 mRNA Stability
- PMID: 39614437
- DOI: 10.31083/j.fbl2911395
CELF6 as an Oncogene in Colorectal Cancer: Targeting Stem-Cell-Like Properties Through Modulation of HOXA5 mRNA Stability
Abstract
Background: Emerging evidence indicates the essential role of cancer stem cells (CSCs) in the development and progression of various cancers, including colorectal cancer (CRC). CELF6, a member of the cytosine-uridine-guanine-binding protein (CUG-BP), Elav-like family (CELF), has been reported to be downregulated in CRC tissues. This study aims to elucidate the role and underlying mechanisms of CELF6 in CRC progression.
Methods: The expression levels and prognostic significance of CELF6, along with its association with homeobox A5 (HOXA5), were analyzed using University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN), PrognoScan, and Tumor Immune Estimation Resource (TIMER) databases. The expression of CELF6 was further assessed through quantitative real-time polymerase chain reaction (qRT-PCR), immunoblotting, and immunohistochemistry. Both in vitro and in vivo experiments were conducted to investigate the effects of CELF6 on CRC cell proliferation, stemness and tumorigenesis, and to elucidate the molecular mechanisms.
Results: CELF6 was found to be downregulated in CRC and was associated with poor prognosis. Functional studies revealed that overexpression of CELF6 resulted in decreased CRC cell proliferation and stemness in vitro, reduced tumor growth in vivo, and induced G1 phase cell cycle arrest. Mechanistically, CELF6 regulated the expression of HOXA5 by modulating its mRNA stability. Furthermore, the knockdown of HOXA5 reversed the inhibitory effects of CELF6 on CRC cell proliferation and stemness, demonstrating that silencing HOXA5 counteracted the suppressive effects of CELF6.
Conclusions: This study is the first to identify CELF6 as a suppressor of stemness and a modulator of CRC progression. These findings provide new insights into the role of CELF6 in CRC and highlight its potential as a novel therapeutic target.
Keywords: CELF6; HOXA5; cancer stemness; colorectal cancer; proliferation.
© 2024 The Author(s). Published by IMR Press.
Similar articles
-
DR6 Augments Colorectal Cancer Cell Growth, Invasion, and Stemness by Activating AKT/NF-κB Pathway.Biochem Genet. 2025 Feb;63(1):606-622. doi: 10.1007/s10528-024-10673-0. Epub 2024 Mar 13. Biochem Genet. 2025. PMID: 38478147 Free PMC article.
-
CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.Breast Cancer Res Treat. 2020 Aug;183(1):71-82. doi: 10.1007/s10549-020-05753-9. Epub 2020 Jun 29. Breast Cancer Res Treat. 2020. PMID: 32601971
-
MiR-3622a-3p acts as a tumor suppressor in colorectal cancer by reducing stemness features and EMT through targeting spalt-like transcription factor 4.Cell Death Dis. 2020 Jul 27;11(7):592. doi: 10.1038/s41419-020-02789-z. Cell Death Dis. 2020. PMID: 32719361 Free PMC article.
-
KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway.Sci Rep. 2016 Feb 5;6:20460. doi: 10.1038/srep20460. Sci Rep. 2016. PMID: 26847701 Free PMC article.
-
Dark force rising: Reawakening and targeting of fetal-like stem cells in colorectal cancer.Cell Rep. 2024 Jun 25;43(6):114270. doi: 10.1016/j.celrep.2024.114270. Epub 2024 May 23. Cell Rep. 2024. PMID: 38787726 Review.
Cited by
-
Overexpression of KRAS enhanced the stemness of esophageal cancer cells inhibited by overexpression of circ0043898.BMC Cancer. 2025 Jul 1;25(1):1039. doi: 10.1186/s12885-025-14358-8. BMC Cancer. 2025. PMID: 40597918 Free PMC article.
-
The mechanism of Shancigu and its monomer in the development of colorectal cancer based on network pharmacology.Sci Rep. 2025 Jul 2;15(1):23186. doi: 10.1038/s41598-025-04795-7. Sci Rep. 2025. PMID: 40603959 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials